問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of Pediatrics

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

林鴻銓Lin, Horng-Chyuan
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林鴻銓

List

58Cases

2010-08-01 - 2011-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-03-01 - 2017-07-31

Phase II

A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

  • Condition/Disease

    Influenza A

  • Test Drug

    MHAA4549A

Participate Sites
5Sites

Study ended4Sites

歐聰億
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2011-05-01 - 2013-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2011-01-01 - 2015-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2006-12-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2010-03-01 - 2012-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-01-04 - 2023-12-31

Phase III

A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab

  • Condition/Disease

    severe asthmatic participants with an eosinophilic phenotype

  • Test Drug

    GSK3511294

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2022-09-30 - 2025-05-31

Phase III

A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744

  • Condition/Disease

    Asthma

  • Test Drug

    GSK3511294

Participate Sites
9Sites

Recruiting9Sites

2022-12-01 - 2026-07-03

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2008-12-01 - 2012-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB